SOUTHERN MEDICAL SCIENCE CO., LTD.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Development of an Automated Instrument for the Isolation of Adipose-Derived Stem Cells (ADSCs)
The content above was translated by Ai
Founded Year
2017
Unified Business No.
59249323
Status
Closed
Number of Employees
0
Total Paid-in
Capital
- (NT$)
Location of Company
Taiwan
, Taipei City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
SOUTHERN MEDICAL SCIENCE CO., LTD. is dedicated to the application of animal and human adipose-derived mesenchymal stem cells, and provides high-quality services including pet adipose-derived mesenchymal stem cell services. SOUTHERN MEDICAL SCIENCE CO., LTD. aims to research, develop, manufacture, and market a machine that isolates and purifies adipose-derived mesenchymal stem cells (ADSCs) within a short timeframe (approximately 1.5 hours) to meet the scheduling demands of general surgery. This brand-new medical device effectively isolates and screens a sufficient quantity of ADSCs from subcutaneous fat through a sterile process in the operating room for tissue reconstruction in regenerative medicine. The advantage of this adipose-derived mesenchymal stem cell isolation machine lies in its ability to rapidly, stably, and efficiently isolate stem cells, allowing individuals to use their own stem cells for tissue reconstruction. Following its establishment, the company will prioritize pet therapy, providing rapid autologous isolation as well as allogeneic adipose-derived mesenchymal stem cells. In the field of human regenerative medicine, the company aims to obtain medical device regulatory certifications in various countries in the future, with the expectation of applying this technology to human regenerative medicine worldwide.
The content above was translated by Ai
